Market Overview

Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

Related CYCC
The Week Ahead: Earnings, Earnings, And More Earnings
12 Biggest Mid-Day Losers For Friday
Cyclacel optimistic with subgroup of patients in failed late-stage study of sapacitabine; investors not on board, shares down 7% (Seeking Alpha)

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.

The poster's abstract details are as follows:

Abstract: 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Title: Treated with Sapacitabine and Decitabine Administered in Alternating Cycles Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time   Hall B1-B2, Level 1, Building B (Georgia World Congress Center) Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II     Poster board: The abstract is available online at:

Posted-In: News


Related Articles (CYCC + CYCCP)

View Comments and Join the Discussion!

Partner Center